Trinity Biotech Enters Into $81M Loan Facility To Refinance Existing Debt

Trinity Biotech plc TRIB has entered into an $81.25 million loan facility to refinance the existing $99.9 million of exchangeable senior notes.

  • The Company entered into an $81.25 million senior secured term loan credit facility with Perceptive Advisors.
  • Under the exchange agreement, each holder has agreed to exchange their Notes at a discount to par and receive $0.87 of cash and $0.08 of Trinity's ADS. 
  • Completing these pending transactions will improve the Company's capital structure by reducing gross debt by approximately $19 million. The Company has no material debt maturities in the next four years.
  • Trinity reported Q3 sales of $22 million, down 31% Y/Y, beating the consensus of $26 million.
  • Point-of-Care revenues almost doubled to $4.1 million attributable to higher HIV revenues from Africa-related sales.
  • Clinical Laboratory revenues decreased 40% to $17.9 million, mainly due to lower revenues within the COVID-19 related portfolio of products.
  • Gross margin contracted from 52.4% to 40.4%. Operating profit reached $2.8 million.
  • Price Action: TRIB shares are up 2.38% at $1.72 during the premarket session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsPenny StocksHealth CareFinancingMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!